Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.
Luminal breast cancer
heterogeneity
personalized treatment
triple negative
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
17
04
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
4
6
2020
Statut:
epublish
Résumé
Breast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understanding of the tumor biology, the disease heterogeneity and the prognosis leading to the discovery of new modalities of targeted therapies and opening horizons toward a more personalized medicine. In recent years, many therapeutic options emerged in the field of metastatic breast carcinoma, especially for the luminal subtypes. They were able to transform the course of the disease while maintaining quality of life. However, the options are still limited for triple-negative breast cancer, but the better knowledge of its complex biology and the discovery of molecular targets are promising for more efficient novel therapies.
Identifiants
pubmed: 31069063
doi: 10.12688/f1000research.17542.1
pmc: PMC6492227
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
Cancer Treat Rev. 2018 Jan;62:110-122
pubmed: 29202431
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
pubmed: 20586616
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213
pubmed: 29457921
Front Med (Lausanne). 2018 Jan 30;5:9
pubmed: 29441349
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Medicine (Baltimore). 2016 Aug;95(35):e4614
pubmed: 27583878
Am Soc Clin Oncol Educ Book. 2018 May 23;38:56-64
pubmed: 30231387
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2018 Nov 1;36(31):3134-3143
pubmed: 30240327
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Am J Cancer Res. 2014 Jul 16;4(4):353-68
pubmed: 25057438
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Br J Cancer. 2018 Jul;119(2):141-152
pubmed: 29867226
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
J Cancer Res Ther. 2015 Jul-Sep;11(3):508-13
pubmed: 26458575
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Br J Cancer. 2018 Jul;119(1):4-11
pubmed: 29808015
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
Clin Breast Cancer. 2016 Oct;16(5):418-423
pubmed: 27265061
Cancer Microenviron. 2013 Aug;6(2):117-22
pubmed: 23108700
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Semin Cancer Biol. 2018 Oct;52(Pt 1):56-73
pubmed: 28882552
Nat Med. 2011 Mar;17(3):283-4
pubmed: 21383736
J Clin Invest. 2011 Oct;121(10):3786-8
pubmed: 21965334
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Clin Cancer Res. 2017 Jun 1;23(11):2617-2629
pubmed: 28572256
Breast Cancer Res Treat. 2018 Aug;170(3):535-545
pubmed: 29654415
Breast. 2019 Feb;43:8-17
pubmed: 30359883
Am Soc Clin Oncol Educ Book. 2015;:e31-9
pubmed: 25993190
Cancer Res. 2018 Feb 15;78(4):1110-1122
pubmed: 29233927
J Clin Oncol. 2015 May 10;33(14):1609-19
pubmed: 25847941
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Oncologist. 2011;16 Suppl 1:1-11
pubmed: 21278435
Genes Dis. 2018 May 12;5(2):77-106
pubmed: 30258937
JCO Precis Oncol. 2017 Nov;1:1-13
pubmed: 35172494
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
J Clin Oncol. 2018 Mar 20;36(9):884-890
pubmed: 29373071
Lancet Oncol. 2016 Jun;17(6):811-821
pubmed: 27155741
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
J Pathol. 2017 Jan;241(2):208-218
pubmed: 27861897
Cancer Treat Rev. 2018 Feb;63:122-134
pubmed: 29287242
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Ann Oncol. 2018 Apr 1;29(4):888-894
pubmed: 29360932
Oncotarget. 2017 Jun 20;8(25):40434-40453
pubmed: 28467815
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882